Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6397 USD | -0.20% | -0.91% | -14.20% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Financials (USD)
Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 13.52M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 64.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 45.1 x |
P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.77
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Traws Pharma, Inc.
1 day | -0.20% | ||
1 week | -0.91% | ||
Current month | -3.08% | ||
1 month | -4.52% | ||
3 months | -6.06% | ||
6 months | -2.91% | ||
Current year | -14.20% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 0.6397 | -0.20% | 45,383 |
24-05-17 | 0.641 | -0.25% | 55,246 |
24-05-16 | 0.6426 | -2.25% | 51,288 |
24-05-15 | 0.6574 | +1.12% | 28,934 |
24-05-14 | 0.6501 | +0.70% | 53,056 |
Delayed Quote Nasdaq, May 20, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.20% | 13.52M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- TRAW Stock